Qiming Venture Partners and Founding Managing Partner Duane Kuang Named to Global Best Investment Institutions List
From one angle, this reflects China's influence in the global private equity market.
The 4th Davos Global FOF Summit was recently held successfully in Davos, Switzerland. At the summit, the Global FOF Association released its 2025 Global Best Investment Institutions list with an awards ceremony. The list was compiled through nominations and scoring by investment associations across Europe, the United States, the Middle East, and other regions.
This year's selection included lists such as the Global Top 50 Funds, Global Top 30 VC/PE Investors, and Global Top 50 FOFs. Qiming Venture Partners was named to the Global Top 50 Funds list, and Duane Kuang, Founding Managing Partner of Qiming Venture Partners, was named to the Global Top 30 VC/PE Investors list.
Qiming Venture Partners Named to Global Top 50 Funds
Duane Kuang, Founding Managing Partner of Qiming Venture Partners Named to Global Top 30 VC/PE Investors
The Global FOF Association has published its annual Global Best Investment Institutions list for seven consecutive years. In this year's rankings, Chinese investment institutions and investors accounted for nearly 30% — a reflection, in part, of China's influence in the global private equity market.
The China FOF Research Center noted that as China's equity investment industry matures and develops, Chinese investment power will continue to rise globally, with more Chinese names appearing on global investment rankings and drawing greater worldwide attention.
Source | China FOF Research Center
Past Highlights
5 AI IPOs in 7 Months, Qiming Venture Partners: Investing in AI Is the Greatest Certainty in Chinese Investment Over the Next Two Decades Qiming Honors | 5 Qiming Venture Partners Investors Named to ChinaVenture 2025 Annual Investors List Qiming Honors | 5 Qiming Venture Partners Investors Named to Forbes China 2025 Top 100 Venture Capitalists List
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management of $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many of Qiming Venture Partners' portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ:HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ:WRD, 00800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu AI (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), SinoCellTech (688520.SH), Insilico Medicine (03696.HK), Arbutus Biopharma, Yuanxin Technology, MediLink Therapeutics, LaNova Medicines, StepFun, and others.